Correlated Drug Terms (4)

---

	Name (Synonyms)	Correlation
drug1269	Itraconazole Wiki	0.71
drug2093	Rifampin Wiki	0.71
drug332	Best Practice Wiki	0.58
drug2527	Tocilizumab Wiki	0.19

Correlated MeSH Terms (7)

---

	Name (Synonyms)	Correlation
D003324	Coronary Artery Disease NIH	0.50
D007676	Kidney Failure, Chronic NIH	0.41
D029424	Pulmonary Disease, Chronic Obstructive NIH	0.35
D008173	Lung Diseases, Obstructive NIH	0.33
D020521	Stroke NIH	0.32
D009369	Neoplasms, NIH	0.22
D007239	Infection NIH	0.06

Correlated HPO Terms (5)

---

	Name (Synonyms)	Correlation
HP:0001677	Coronary artery atherosclerosis HPO	0.50
HP:0006510	Chronic pulmonary obstruction HPO	0.35
HP:0006536	Pulmonary obstruction HPO	0.33
HP:0001297	Stroke HPO	0.32
HP:0002664	Neoplasm HPO	0.22

Primary Outcomes

Description: Cmax is defined as maximum plasma concentration.

Measure: Cohort 1 and 2: Maximum Plasma Concentration (Cmax) of Lazertinib

Time: Predose up to 120 hours post dose

---

Description: AUC (0-120h) is defined as area under the plasma concentration-time curve from time 0 to 120 hours postdose.

Measure: Cohort 1 and 2: Area Under the Plasma Concentration-time Curve from Time 0 to 120 Hours (AUC [0-120h]) of Lazertinib

Time: Predose up to 120 hours post dose

---

Description: AUC (0-last) is defined as area under the plasma concentration-time curve from time 0 to time of last quantifiable timepoint.

Measure: Cohort 1 and 2: Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Timepoint (AUC [0-last]) of Lazertinib

Time: Predose up to 120 hours post dose

---

Description: AUC (0-inf) is defined as area under the plasma concentration-time curve from time 0 to infinity, calculated as the sum of AUC(0-last)+C(last)/ lambda(z), where C(last) is the last observed measurable (non-below limit of quantification) concentration.

Measure: Cohort 1 and 2: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUC [0-inf]) of Lazertinib

Time: Predose up to 120 hours post dose

---

Description: %AUC (0-inf),ex is defined as percentage of area under the plasma concentration from time zero to infinite time obtained by extrapolation, calculated as (AUC [0-infinity] minus AUC [0-last]/AUC [0-infinity])*100.

Measure: Cohort 1 and 2: Percentage of Area Under the Plasma Concentration from time Zero to Infinite time obtained by Extrapolation (%AUC [0-inf],ex) of Lazertinib

Time: Predose up to 120 hours post dose

---

Secondary Outcomes

Description: An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.

Measure: Cohort 1 and Cohort 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

Time: Up to 65 days (Cohort 1) and up to 70 days (Cohort 2)

---